What is Biometry?
Biometry operates a sophisticated platform designed for the remote monitoring and management of patients with chronic conditions, with a primary focus on asthma. The system leverages proprietary sensors to measure key biomarkers, such as Fractional Exhaled Nitric Oxide (FeNO), thereby assessing medication adherence and treatment efficacy. The associated application delivers actionable insights and personalized predictive risk models, empowering patients to proactively manage their asthma. Furthermore, Biometry offers scalable, CDC-recognized self-management programs aimed at enhancing patient education and reducing overall healthcare expenditures.
How much funding has Biometry raised?
Biometry has raised a total of $5M across 1 funding round:
Angel/Seed
$5M
Angel/Seed (2024): $5M with participation from CareSource, Dexcom, and Elevate Ventures
Key Investors in Biometry
CareSource
CareSource is a national leader in managed care, administering one of the nation's largest Medicaid managed care plans and offering a wide range of health insurance programs. Their investment suggests a focus on improving patient outcomes and reducing healthcare costs through innovative solutions.
Dexcom
Dexcom is a leading medical technology company specializing in continuous glucose monitoring systems. Their participation indicates an interest in remote patient monitoring technologies and the intersection of hardware and software in chronic disease management.
Elevate Ventures
Elevate Ventures is an Indiana-based venture capital firm that invests in early-stage, innovation-driven companies. Their involvement highlights Biometry's potential for growth and innovation within the health tech sector.
What's next for Biometry?
With this latest round of major enterprise-level funding, Biometry is poised for significant expansion and further development of its predictive analytics and patient engagement tools. The strategic investment will likely fuel advancements in sensor technology, broaden the platform's reach to new chronic conditions, and enhance its data-driven insights for healthcare providers. This capital injection signals a strong market validation and positions Biometry to scale its operations and solidify its role in the digital health landscape.
See full Biometry company page
